معرفی
Kipp Weiskopf is a Valhalla Fellow at the Whitehead Institute for Biomedical Research and an External Affiliated Fellow at MIT's Koch Institute for Integrative Cancer Research. He concurrently serves as a physician at Dana-Farber Cancer Institute, bridging clinical practice with innovative cancer immunology research.
- Education: B.A. in Biology from Amherst College (2007), M.Phil. in Genetics from University of Cambridge (2008), M.D./Ph.D. from Stanford University School of Medicine (2016)
His research focuses on harnessing myeloid cells, particularly macrophages, to combat cancer by targeting immune evasion mechanisms like the CD47/SIRPα pathway. His work has pioneered CD47-blocking therapies that enhance immune recognition of cancer cells and demonstrated their potential in small cell lung cancer and bone marrow transplantation.
Recent publications highlight advancements in macrophage activation for cancer destruction (2024), discovery of MHC class I-LILRB1 immune checkpoint (2017), and SIRPα variant development (2013). These studies reflect his long-term interest in immune-cancer interactions and therapeutic translation.
Scientific Awards & Honors
- National Cancer Institute R01 Grant (2023)
- AACR-AstraZeneca Career Development Award (2022)
- DoD Peer-Reviewed Cancer Research Award (2022)
- ASCO Young Investigator Award (2021)
- Harold Weintraub Graduate Student Award (2014)
- Collegiate Inventors Competition Winner (2013)
- Churchill Scholarship (2007)
Weiskopf's discoveries have directly contributed to multiple clinical trials and spin-out biotech companies including Forty Seven, ALX Oncology, DEM Biopharma, and Solu Therapeutics. His laboratory continues to explore novel myeloid cell activation mechanisms for cancer and life-threatening diseases like COVID-19.
